Free Trial

Arcutis Biotherapeutics (ARQT) Competitors

Arcutis Biotherapeutics logo
$13.73 -0.02 (-0.15%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ARQT vs. LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, AKRO, PCVX, and ADMA

Should you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

Arcutis Biotherapeutics vs. Its Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 6 articles in the media. Legend Biotech's average media sentiment score of 1.44 beat Arcutis Biotherapeutics' score of 1.18 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcutis Biotherapeutics
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Legend Biotech
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arcutis Biotherapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

70.9% of Legend Biotech shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis Biotherapeutics$196.54M8.33-$140.04M-$1.04-13.20
Legend Biotech$627.24M10.53-$177.03M-$0.59-60.94

Arcutis Biotherapeutics presently has a consensus target price of $18.80, indicating a potential upside of 36.92%. Legend Biotech has a consensus target price of $74.18, indicating a potential upside of 106.32%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcutis Biotherapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92

Legend Biotech has a net margin of -29.95% compared to Arcutis Biotherapeutics' net margin of -60.95%. Legend Biotech's return on equity of -21.19% beat Arcutis Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcutis Biotherapeutics-60.95% -80.66% -32.94%
Legend Biotech -29.95%-21.19%-13.47%

Summary

Legend Biotech beats Arcutis Biotherapeutics on 11 of the 15 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARQT vs. The Competition

MetricArcutis BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.63B$2.90B$5.50B$8.93B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-13.1521.2826.2519.86
Price / Sales8.33280.14415.14113.78
Price / CashN/A41.8936.4957.06
Price / Book10.177.468.055.38
Net Income-$140.04M-$55.05M$3.16B$248.50M
7 Day Performance-5.11%2.25%1.78%2.78%
1 Month Performance1.86%7.17%4.74%5.84%
1 Year Performance47.65%5.13%35.81%20.06%

Arcutis Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARQT
Arcutis Biotherapeutics
2.0367 of 5 stars
$13.73
-0.1%
$18.80
+36.9%
+43.8%$1.63B$196.54M-13.15150Positive News
LEGN
Legend Biotech
2.4528 of 5 stars
$33.85
-0.4%
$76.20
+125.1%
-21.1%$6.25B$627.24M-57.372,609Positive News
Analyst Forecast
GRFS
Grifols
4.1197 of 5 stars
$8.37
-4.6%
$10.30
+23.1%
+43.3%$6.03B$7.81B7.1523,822Analyst Downgrade
TLX
Telix Pharmaceuticals
N/A$16.39
-4.4%
$22.00
+34.2%
N/A$5.80B$516.72M0.00N/AGap Down
High Trading Volume
TGTX
TG Therapeutics
3.7452 of 5 stars
$36.56
+1.5%
$40.80
+11.6%
+95.0%$5.72B$329M152.33290
LNTH
Lantheus
4.4423 of 5 stars
$80.81
+2.0%
$130.50
+61.5%
-0.7%$5.48B$1.53B22.96700Positive News
NUVL
Nuvalent
3.7087 of 5 stars
$75.98
+1.3%
$115.50
+52.0%
+3.3%$5.39BN/A-17.3140Analyst Upgrade
Insider Trade
AXSM
Axsome Therapeutics
4.6726 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+27.1%$4.96B$385.69M-17.62380Analyst Revision
AKRO
Akero Therapeutics
3.6042 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+122.0%$4.32BN/A-27.7130
PCVX
Vaxcyte
1.7882 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-57.2%$4.24BN/A-8.33160News Coverage
Positive News
ADMA
ADMA Biologics
4.0895 of 5 stars
$17.87
+0.7%
$27.67
+54.8%
+54.8%$4.24B$426.45M21.02530

Related Companies and Tools


This page (NASDAQ:ARQT) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners